Do statins decrease cardiovascular disease at the expense of increasing cancer?

International Journal of Cardiology

Volumn 133, Issue 2, 2009, Pages 254-255

  Goldstein, Mark R ^a   Mascitelli, Luca ^b  

^a Servizio Sanitario ^*  (United States)

^b NONE   (Italy)

Author keywords

Cancer; Cardiovascular disease; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; ETHNIC DIFFERENCE; HUMAN; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LYMPHOMA; NEOPLASM; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN CANCER;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS;

EID: 62049083386     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.11.020     Document Type: Article

References (15)

1. Song Y.M., Sung J., and Kim J.S. Which cholesterol level is related to the lowest mortality in a population with low mean cholesterol level: a 6.4-year follow-up study of 482,472 Korean men. Am J Epidemiol 151 (2000) 739-747
2. Sherwin R.W., Wentworth D.N., Cutler J.A., et al. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA 257 (1987) 943-948
3. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50 (2007) 409-418
4. Newman T.B., and Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA 275 (1996) 55-60
5. Shepherd J., et al., on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
6. Hunt D., et al., for the LIPID Investigators. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 134 (2001) 931-940
7. Sacks F.M., et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
8. Soko S., Glynn R.J., Avorn J., Mogun H., and Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115 (2007) 27-33
9. Blais L., Desgagne A., and Lelorier J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160 (2000) 2363-2368
10. Iwata H., Matsuo K., Hara S., et al. Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 97 2 (2006) 133-138
11. Pedersen T.R., Berg K., Cook T.J., et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156 (1996) 2985-2992
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
13. Hoffmann P., Roumeguere T., and van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355 (2006) 2705-2707
14. Matsuzaki M., Kita T., Mabuchi H., et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia: primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66 (2002) 1087-1095
15. Wenger N.K., et al., for the Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 147 (2007) 1-9